ProCE Banner Activity

Near Future Directions: Promising Strategies Under Investigation

Slideset Download

Download this slideset from a live symposium at ASH 2022 to review emerging investigational agents and combination therapies in CLL.

Released: December 09, 2022

Expiration: December 08, 2023

No longer available for credit.

Share

Faculty

Deborah Stephens

Deborah Stephens, DO

Associate Professor
Director of the CLL Program
Lineberger Comprehensive Cancer Center
University of North Carolina
Chapel Hill, North Carolina

Provided by

Provided by National Comprehensive Cancer Network, in partnership with Clinical Care Options, LLC
ProCE Banner

Supporters

AstraZeneca

BeiGene

Lilly

Pharmacyclics LLC an AbbVie Company and Janssen Biotech Inc

Faculty Disclosure

Primary Author

Deborah Stephens, DO

Associate Professor
Director of the CLL Program
Lineberger Comprehensive Cancer Center
University of North Carolina
Chapel Hill, North Carolina

Deborah Stephens, DO: consultant/advisor/speaker AbbVie/Genentech, AstraZeneca, BeiGene, Celgene/Bristol-Myers Squibb, Epizyme, Lilly, TG Therapeutics; researcher: Merck, Novartis